Patents by Inventor Whitehead Institute for Biomedical Research
Whitehead Institute for Biomedical Research has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190112394Abstract: Methods and reagents for the installation of click chemistry handles on target proteins are provided, as well as modified proteins comprising click chemistry handles. Further, chimeric proteins, for example, bi-specific antibodies, that comprise two proteins conjugated via click chemistry, as well as methods for their generation and use are disclosed herein.Type: ApplicationFiled: September 24, 2018Publication date: April 18, 2019Applicant: Whitehead Institute for Biomedical ResearchInventor: Whitehead Institute for Biomedical Research
-
Publication number: 20130244903Abstract: Disclosed are compositions and methods for modulating expression of genes that function at the step of ER to Golgi trafficking. Compounds that modulate expression of these genes or activity of the encoded proteins can be used to inhibit alpha-synuclein mediated toxicity and used to treat or prevent synucleinopathies such as Parkinson's disease. Also disclosed are methods of identifying inhibitors of alpha-synuclein mediated toxicity.Type: ApplicationFiled: January 18, 2013Publication date: September 19, 2013Applicants: THE CURATORS OF THE UNIVERSITY OF MISSOURI, WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCHInventors: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, THE CURATORS OF THE UNIVERSITY OF MISSOURI
-
Publication number: 20130198875Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must he present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: March 14, 2013Publication date: August 1, 2013Applicants: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V., University of Massachusetts, Whitehead Institute for Biomedical Research, Massachusetts Institute of TechnologyInventors: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V., Massachusetts Institute of Technology, Whitehead Institute of Biomedical Research, University of Massachusetts
-
Publication number: 20130125259Abstract: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3? ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.Type: ApplicationFiled: December 21, 2012Publication date: May 16, 2013Applicants: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V., University Of Massachusetts, Whitehead Institute For Biomedical Research, Massachusetts Institute Of TechnologyInventors: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V., Massachusetts Institute Of Technology, Whitehead Institute For Biomedical Research, University Of Massachusetts
-
Publication number: 20130109089Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.Type: ApplicationFiled: October 5, 2012Publication date: May 2, 2013Applicant: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCHInventor: Whitehead Institute for Biomedical Research
-
Publication number: 20130109090Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.Type: ApplicationFiled: October 5, 2012Publication date: May 2, 2013Applicant: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCHInventor: Whitehead Institute for Biomedical Research
-
Publication number: 20130102080Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.Type: ApplicationFiled: October 5, 2012Publication date: April 25, 2013Applicant: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCHInventor: Whitehead Institute for Biomedical Research
-
Publication number: 20130102074Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.Type: ApplicationFiled: October 5, 2012Publication date: April 25, 2013Applicant: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCHInventor: Whitehead Institute for Biomedical Research
-
Publication number: 20130072485Abstract: The present invention relates to small molecule modulators of mTORC1 and mTORC2, syntheses thereof, and intermediates thereto. Such small molecule modulators are useful in the treatment of proliferative diseases (e.g., benign neoplasms, cancers, inflammatory diseases, autoimmune diseases, diabetic retinopathy) and metabolic diseases. Novel small molecules are provided that inhibit one or more of mTORC1, mTORC2, and PI3K-related proteins. Novel methods of providing soluble mTORC1 and mTORC2 complexes are discussed, as well as methods of using the soluble complexes in a high-throughput manner to screen for inhibitory compounds.Type: ApplicationFiled: November 6, 2012Publication date: March 21, 2013Applicants: Dana-Farber Cancer Institute, Inc., Whitehead Institute for Biomedical ResearchInventors: Whitehead Institute for Biomedical Research, Dana-Farber Cancer Institute, Inc.